Au­toim­mune pa­tients in CAR-T study see strik­ing im­prove­ments across lu­pus and oth­er dis­eases

SAN DIEGO — All of the first 15 au­toim­mune dis­ease pa­tients who re­ceived CAR-T ther­a­py at a Ger­man hos­pi­tal saw the de­bil­i­tat­ing symp­toms of their dis­eases, in­clud­ing lu­pus and myosi­tis, sub­stan­tial­ly im­prove or go away en­tire­ly, ac­cord­ing to new re­search re­sults shared Sat­ur­day.

In 2021, a team of re­searchers from the Uni­ver­si­ty Hos­pi­tal Er­lan­gen be­gan the first study of CAR-T ther­a­py in pa­tients with au­toim­mune dis­eases, mak­ing waves across the field when they an­nounced that the first five pa­tients with lu­pus all went in­to re­mis­sion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.